VIA Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of compounds for the treatment of cardiovascular diseases. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The company went IPO on 2000-04-18. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.
Follow-Up Questions
What is VIA Pharmaceuticals Inc (VIAP)'s P/E Ratio?
The P/E ratio of VIA Pharmaceuticals Inc is 0
Who is the CEO of VIA Pharmaceuticals Inc?
Dr. Lawrence Cohen is the President of VIA Pharmaceuticals Inc, joining the firm since 2007.
What is the price performance of VIAP stock?
The current price of VIAP is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for VIA Pharmaceuticals Inc?
VIA Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is VIA Pharmaceuticals Inc market cap?
VIA Pharmaceuticals Inc's current market cap is $0
